Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07148427 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University